In the IFIGENIA study, adding NAC 600 mg/day to prednisone and azathioprine slowed lung function decline and improved Diffusing Capacity of the Lung for Carbon Monoxide (DLCO), especially in early IPF (136, 137)
In the PIONEER-6 study, proliferative retinopathy and macular edema requiring treatment were exclusion criteria
The tirzepatide to semaglutide transition typically involves starting semaglutide at a moderate dose (0.5mg or 1.0mg weekly) rather than the standard 0.25mg starting dose, since the body is already adapted to GLP-1 receptor activation
While the biological rationale is compelling, definitive proof that GLP-1 medications prevent or treat Alzheimer's disease in humans remains lacking
Trust Signals Key Takeaways All BPC-157 efficacy evidence comes from animal models
A Hybrid In Silico and Tumor-on-a-Chip Approach to Model Targeted Protein Behavior in 3D Microenvironments